Donor-recipient HLA compatibility and the immunology of solid organ transplant rejection
The human leukocyte antigen (HLA) system, encoded by the Major Histocompatibility Complex (MHC) on chromosome 6, is the single most important genetic barrier to solid organ transplantation. Before a donor organ is ever allocated, laboratories type both donor and recipient HLA alleles and screen the recipient's serum for antibodies that could destroy the graft on contact.
The MHC is the most gene-dense and polymorphic region of the human genome. It encodes two structurally distinct classes of transplant-relevant molecules:
• Class I (HLA-A, -B, -C): expressed on essentially all nucleated cells, including graft vascular endothelium. Each is a heterodimer of a polymorphic heavy chain (encoded in the MHC) non-covalently paired with invariant β2-microglobulin. Class I molecules present peptides from the cell's own cytosol to CD8+ cytotoxic T cells.
• Class II (HLA-DR, -DQ, -DP): normally restricted to "professional" antigen-presenting cells — dendritic cells, B cells, macrophages, and activated endothelium — where they present extracellularly-derived peptides to CD4+ helper T cells.
Both classes are extraordinarily polymorphic: HLA-B alone has over 9,000 catalogued alleles. This diversity evolved to maximize population-level resistance to pathogens (a diverse peptide-presentation repertoire), but it is precisely this diversity that makes finding an immunologically "silent" donor-recipient pair so difficult — most unrelated donor-recipient pairs differ at multiple loci.
Each parent contributes one HLA haplotype (a linked set of A, B, C, DR, DQ alleles inherited as a block due to tight genetic linkage), so full siblings have a 25% chance of being a complete 2-haplotype (0-mismatch) match — the best possible living-donor scenario.
Modern histocompatibility labs no longer rely on the original serologic (antibody panel) typing; molecular methods now dominate:
• SSO (sequence-specific oligonucleotide) probing: PCR-amplified HLA DNA is hybridized to a panel of bead-bound probes (Luminex platform), giving allele-group resolution in hours. • SSP (sequence-specific primer) PCR: amplification only occurs if primers matching a specific allele bind — presence/absence of a band indicates the allele. • Next-generation sequencing (NGS): full-gene, phase-resolved sequencing giving unambiguous high-resolution (4-digit) typing, increasingly the clinical standard, especially for identifying eplet-level mismatches.
The classic clinical shorthand is the "6-antigen match": two alleles each at HLA-A, -B, and -DR, for a maximum of 6 matched antigens (0–6 mismatches). HLA-C and -DQ are typed and increasingly incorporated into eplet/epitope matching algorithms, but historically carried less weight in allocation because their surface expression and immunogenicity were considered lower — a view now being revised as antibody data accumulate.
Recipients can carry pre-formed anti-HLA antibodies from prior transplants, blood transfusions, or pregnancy (fetal HLA inherited from the father). These antibodies are screened long before a specific donor is identified:
• PRA / calculated PRA (cPRA): recipient serum is tested against a panel representing the HLA diversity of the donor population (historically by CDC, now mainly by solid-phase Luminex single-antigen bead assays). The percentage of panel specificities reacted against estimates how "sensitized" a patient is and how hard it will be to find a compatible donor. • Physical crossmatch: recipient serum is mixed directly with donor lymphocytes. – CDC (complement-dependent cytotoxicity) crossmatch: if recipient antibody binds donor cells and fixes complement, the cells die (visualized with dye) — a positive result is an absolute contraindication to transplant. – Flow cytometry crossmatch (FCXM): far more sensitive; detects antibody binding even without complement fixation or cell death, revealing low-level DSA the CDC test misses. • Virtual crossmatch: donor HLA typing is compared computationally against the recipient's previously characterized single-antigen bead antibody profile — allowing a "predicted" crossmatch result before organs (especially deceased-donor kidneys, which cannot wait for a physical crossmatch) are shipped.
A positive CDC crossmatch against T cells (class I reactive) is an absolute contraindication to transplant in almost all circumstances — proceeding anyway risks hyperacute rejection and total, irreversible graft loss within minutes to hours.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| HLA-A / -B / -C (Class I) | All nucleated cells incl. endothelium | Presents cytosolic peptides to CD8+ T cells | Core of the classic 6-Ag (A+B+DR) match |
| HLA-DR (Class II) | APCs, activated endothelium | Presents extracellular peptides to CD4+ T cells | Most immunogenic locus per mismatch |
| HLA-DQ (Class II) | APCs, activated endothelium | Presents extracellular peptides to CD4+ T cells | Leading cause of de novo DSA post-transplant |
| HLA-C (Class I) | All nucleated cells | Also ligand for NK cell KIR receptors | Increasingly typed for eplet-level matching |
When donor and recipient share most or all HLA alleles, the recipient immune system has very little "foreign" surface to recognize. Match quality is not all-or-nothing: it exists on a continuum from a 0-mismatch identical-twin graft to a fully mismatched, highly immunogenic organ, and outcomes track that continuum closely.
T cell receptors and antibodies do not recognize "HLA-A2" as an abstract label — they recognize the precise three-dimensional surface of the folded molecule, including the peptide sitting in its groove. A mismatched HLA molecule differs from the recipient's own by anywhere from one amino acid to dozens, changing the shape of surface loops that antibodies bind (eplets) and altering which self-peptides are displayed and how they look to T cells (direct allorecognition, covered in Stage 4).
A well-matched graft minimizes both: (1) the direct pathway "danger signal" from intact donor HLA on graft antigen-presenting cells, and (2) the number of unique eplets against which the recipient could eventually raise de novo antibodies. Fewer mismatches simply means less immunological "surface area" for the alloimmune response to engage.
Traditional matching counts whole HLA antigens as matched or mismatched, but this is a blunt instrument — two "different" HLA-B alleles might share nearly all of their antibody-accessible surface, while two others might differ at every exposed loop.
Eplet matching (implemented in software such as HLAMatchmaker) instead compares the actual polymorphic amino acid patches — eplets — that antibodies can physically bind. This finer-grained approach better predicts which mismatches will actually provoke a de novo donor-specific antibody response, and is increasingly used for:
• Prioritizing organ allocation toward genuinely low-immunogenicity donor-recipient pairs • Guiding immunosuppression intensity (higher eplet mismatch load → more aggressive maintenance therapy) • Explaining why two patients with an identical "4 antigen mismatch" score can have very different real-world rejection rates.
Registry data consistently show a stepwise survival advantage with each additional matched HLA antigen — even in the era of modern immunosuppression, a 0-mismatch kidney graft has meaningfully better long-term survival than a 6-mismatch graft from an otherwise identical donor.
HLA match quality is one of several factors determining outcome, alongside cold ischemia time, donor age and organ quality, ABO compatibility, recipient sensitization history, and adherence to immunosuppression. Modern calcineurin-inhibitor-based regimens have narrowed — but not eliminated — the survival gap between well-matched and poorly-matched grafts.
This is why even an excellent HLA match does not remove the need for baseline immunosuppression: some degree of alloreactivity persists even against "matched" grafts because clinical matching is rarely a perfect 0-mismatch at every locus (DQ and DP are often not fully matched), and because non-HLA antigens (minor histocompatibility antigens, MICA, endothelial autoantigens) can still provoke a low-level immune response.
Hyperacute rejection is the fastest and most destructive form of graft loss: within minutes of vascular anastomosis and reperfusion, pre-formed recipient antibodies bind donor endothelial HLA (or ABO blood group antigens), fix complement, and trigger a fulminant thrombotic cascade that infarcts the entire organ before it ever has a chance to function.
Hyperacute rejection requires that the recipient already possess circulating antibody specific for donor HLA class I (or, classically, ABO blood-group antigens) at the moment of graft reperfusion — this is exactly what pre-transplant crossmatching is designed to detect and prevent.
The sequence unfolds explosively fast:
1. Antibody binding: circulating IgG (or IgM) immediately coats donor vascular endothelial cells as blood flow is restored. 2. Classical complement activation: bound antibody Fc regions recruit C1q, triggering the classical complement cascade (C1 → C4 → C2 → C3 → C5) culminating in the membrane attack complex (C5b-9), which perforates endothelial cell membranes. 3. Endothelial activation and loss of anticoagulant surface: injured endothelium exposes subendothelial collagen and tissue factor, losing its normal thromboresistant properties (loss of thrombomodulin/heparan sulfate activity). 4. Platelet aggregation and diffuse microvascular thrombosis: the exposed prothrombotic surface triggers widespread clot formation throughout the graft microvasculature within minutes. 5. Ischemic infarction: thrombosed vessels cut off all blood flow; the organ becomes mottled, cyanotic, and soft on the operating table — a process surgeons can literally watch happen in real time.
Because hyperacute rejection is essentially untreatable once triggered — there is no immunosuppressive regimen fast enough to halt a complement cascade already in progress — prevention through mandatory pre-transplant crossmatching is the only effective strategy.
Recipients become "sensitized" (PRA-positive) through prior HLA exposure:
• Pregnancy: fetal cells express paternal HLA antigens foreign to the mother; even a single prior pregnancy can generate lasting anti-HLA antibodies. • Blood transfusion: leukocytes in non-leukoreduced blood products carry HLA class I and II antigens. • Prior transplantation: a previous graft loss is one of the strongest sensitizing events, particularly if immunosuppression was withdrawn and the failed graft "re-primed" memory B cells. • Prior transplant nephrectomy or graft retention: retained failed graft tissue can continue stimulating antibody production long after clinical failure.
Highly sensitized patients (cPRA >80–98%) may wait years for a compatible organ, since most potential donors will crossmatch positive against their antibody repertoire.
For highly sensitized patients, several strategies can lower antibody titers enough to permit transplantation across a previously prohibitive antibody barrier:
• Plasmapheresis / plasma exchange: physically removes circulating antibody from plasma, often combined with low-dose IVIG replacement. • High-dose IVIG: modulates antibody production and provides anti-idiotypic neutralization. • Rituximab (anti-CD20): depletes B cells, reducing new antibody production (though existing plasma cells, which lack CD20, are unaffected). • Bortezomib / other plasma-cell-directed agents: targets long-lived antibody-secreting plasma cells directly. • Eculizumab (anti-C5): blocks terminal complement activation, used in refractory antibody-mediated rejection as a rescue therapy. • Kidney paired donation / exchange programs: rather than desensitizing the patient, match them instead to a different, crossmatch-negative donor within a chain or pool of incompatible pairs.
Even after desensitization, patients remain at elevated risk for later antibody-mediated rejection and require closer post-transplant DSA monitoring.
Acute rejection is the immune system's delayed, learned response to a mismatched graft: over days to weeks, recipient T cells recognize donor HLA through direct, indirect, and semi-direct pathways, infiltrate the organ, and mount a coordinated cellular attack — often accompanied by newly formed (de novo) donor-specific antibodies.
Recipient T cells can recognize donor HLA through three distinct, non-mutually-exclusive routes:
• Direct pathway: recipient T cell receptors bind intact, unprocessed donor HLA molecules displayed on donor antigen-presenting cells (passenger leukocytes carried within the graft, or activated graft endothelium). Because T cell receptors cross-react broadly with foreign HLA shapes, the frequency of directly alloreactive T cells is remarkably high (1–10% of all T cells) — orders of magnitude greater than the frequency responding to any single conventional pathogen. This pathway dominates early acute rejection, while donor passenger APCs are still present, and gradually wanes as they are cleared.
• Indirect pathway: recipient antigen-presenting cells engulf shed/degraded donor HLA protein and present derived peptides, bound in the groove of the recipient's own HLA molecules, to recipient CD4+ T cells — conventional, low-frequency antigen presentation. This pathway persists indefinitely (donor protein continually sheds from the graft) and is the dominant driver of chronic rejection and the licensing of de novo antibody production by B cells.
• Semi-direct pathway: recipient dendritic cells acquire and display intact donor HLA-peptide complexes (via membrane exchange or exosome uptake) without processing them, combining features of both — allowing a single recipient APC to simultaneously stimulate direct-pathway CD8+ T cells and, via co-presented processed peptide, indirect-pathway CD4+ T cells.
The exceptionally high frequency of directly alloreactive T cells — far higher than for any pathogen a person will ever encounter — is why allograft rejection can be so fast and forceful, and why lifelong immunosuppression is required even against well-matched grafts.
Once alloreactive CD4+ and CD8+ T cells are activated (co-stimulation via CD28-B7, cytokine signals from IL-2 and others), they proliferate clonally and traffic to the graft along chemokine gradients:
• CD8+ cytotoxic T cells directly kill graft parenchymal and endothelial cells via perforin/granzyme release and Fas-FasL engagement. • CD4+ helper T cells orchestrate the response — secreting IFN-γ and other cytokines that activate macrophages, upregulate graft HLA expression (amplifying the target), and provide help to alloreactive B cells. • Infiltrating macrophages and NK cells contribute additional tissue injury and cytokine amplification. • Alloreactive B cells, licensed largely through indirect-pathway CD4+ T cell help, differentiate into plasma cells producing de novo donor-specific antibodies (dnDSA) — adding an antibody-mediated rejection (AMR) component that can occur alongside T cell-mediated rejection (TCMR), or independently, often weeks to months later.
Biopsy findings are graded by the Banff classification: TCMR is staged by degree of interstitial inflammation and tubulitis (Banff IA–III for kidney), while AMR is defined by microvascular inflammation (glomerulitis/peritubular capillaritis), C4d complement staining in peritubular capillaries, and detectable circulating DSA.
Modern protocols combine agents that block different steps of T and B cell activation:
• Induction (peri-transplant): IL-2 receptor antagonists (basiliximab) or lymphocyte-depleting agents (anti-thymocyte globulin, alemtuzumab) blunt the earliest, most intense alloimmune surge. • Maintenance — calcineurin inhibitors (tacrolimus, cyclosporine): block IL-2 transcription downstream of TCR signaling, the backbone of most regimens. • Antimetabolites (mycophenolate mofetil, azathioprine): inhibit lymphocyte proliferation by blocking purine synthesis. • Corticosteroids: broad anti-inflammatory and lymphocyte-suppressive effect, used at induction and to treat acute rejection episodes (pulse-dose methylprednisolone). • mTOR inhibitors (sirolimus, everolimus): block cytokine-driven proliferation; sometimes substituted for calcineurin inhibitors to spare nephrotoxicity. • AMR-specific therapy: plasmapheresis, IVIG, rituximab, and complement blockade as in hyperacute rejection, plus emerging agents targeting the IL-6/IL-6R axis and proteasome.
Every one of these agents blunts the immune system globally, not just its alloreactive arm — the central clinical tension of transplantation is balancing enough immunosuppression to prevent rejection against the resulting increased risk of opportunistic infection (CMV, BK polyomavirus, fungal disease) and malignancy (post-transplant lymphoproliferative disease, skin cancers), both of which rise steeply with cumulative immunosuppressive burden.
Chronic rejection is not a single acute event but the cumulative scar tissue of years of low-grade immune activity — repeated subclinical cellular and antibody-mediated injury slowly thickens graft blood vessels, drives fibrosis, and erodes organ function long after the patient has otherwise felt well.
The defining lesion of chronic rejection is transplant (allograft) vasculopathy — also called chronic allograft nephropathy in kidneys or cardiac allograft vasculopathy in hearts: concentric intimal thickening of graft arteries caused by proliferation of smooth-muscle-like cells within the vessel wall.
Unlike native atherosclerosis, transplant vasculopathy is diffuse and circumferential rather than focal and eccentric, reflecting its immune (not purely lipid-driven) origin. Repeated low-grade endothelial injury — from recurrent subclinical T cell-mediated inflammation, chronic antibody binding to donor endothelial HLA, and complement-independent antibody effects (direct endothelial activation, NK cell antibody-dependent cellular cytotoxicity) — triggers a chronic wound-healing response: intimal smooth muscle proliferation, extracellular matrix deposition, and progressive luminal narrowing.
The narrowed vessels chronically under-perfuse downstream tissue, driving interstitial fibrosis and tubular atrophy (kidney) or diffuse myocardial fibrosis (heart) — irreversible, slowly accumulating damage that eventually manifests as declining graft function.
Because transplant vasculopathy is diffuse and involves the full length of graft vessels, it is not amenable to stenting or bypass the way focal atherosclerotic disease is — the only durable fix for a chronically failing graft is re-transplantation.
De novo donor-specific antibodies that emerge months to years post-transplant (most often against HLA-DQ, the most immunogenic class II locus) are now recognized as the single strongest predictor of late graft loss. Even at low, sometimes barely detectable titers, chronic DSA binding to graft endothelium produces:
• Chronic microvascular inflammation: persistent glomerulitis and peritubular capillaritis on biopsy, often with linear C4d deposition marking ongoing complement fixation. • Transplant glomerulopathy: DSA-driven double-contouring of the glomerular basement membrane from repeated subclinical endothelial injury and repair. • Accelerated intimal thickening: chronic low-level complement and Fc-receptor-mediated endothelial activation compounds the cellular contribution to vasculopathy.
Because this process is frequently subclinical (normal or slowly rising creatinine, no acute symptoms), many centers now perform protocol (surveillance) biopsies and periodic DSA monitoring in higher-risk recipients to catch chronic antibody-mediated rejection before irreversible fibrosis accumulates.
Chronic rejection risk compounds several of the mechanisms covered in earlier stages plus non-immune contributors:
• Cumulative HLA mismatch burden and eplet load (Stage 1–2): more mismatch means a larger, longer-running indirect-pathway antigen supply feeding chronic T and B cell responses. • Prior acute rejection episodes (Stage 4): each treated episode leaves residual scarring and primes memory alloimmunity, making chronic injury more likely even after apparent recovery. • Under-immunosuppression: non-adherence or minimization of immunosuppression (often to reduce infection/malignancy risk, see Stage 4) is one of the most common preventable causes of late dnDSA formation. • Non-immune injury: calcineurin-inhibitor nephrotoxicity, hypertension, recurrent native disease, and ischemia-reperfusion injury from procurement all compound and accelerate immune-mediated fibrosis.
Currently no therapy reliably reverses established transplant vasculopathy or fibrosis — management focuses on early detection (surveillance biopsy, DSA monitoring), optimizing immunosuppression adherence, and treating modifiable non-immune contributors. This is why transplant tolerance induction (engineering the immune system to permanently accept the graft without ongoing global immunosuppression) and improved HLA/eplet matching at allocation remain major frontiers of transplant research.